Terapio Raises $5M

Austin-based Terapio Corporation, a biotechnology firm developing protein therapeutics, said today that it has raised $5M in an equity funding from Sante Ventures. According to Terapio, it is developing a pipeline of therapeutic applications based on RLIP76, a transport protein which helps move large molecules across cell membranes. The firm is applying the technology to radiation countermeasures, and also towards drug delivery. The company said the new funding will go towards moving its products towards human clinical trials. Terapio's technology was originally licensed from the University of Texas at Arlington, and the firm has previously raised $3.2M from the Texas Emerging Technology Fund, the National Institutes of Health, and angel investors. More information »